Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. CEO Stéphane Bancel reportedly said that he believes the COVID-19 pandemic could be over in a year as vaccine production continues.

Moderna CEO says COVID-19 pandemic could be over in a year

Horizon Pharma

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position REGN, MRNA, VRTX, and HZNP well amid the economic recovery.

4 Top Biotech Stocks to Watch as Economic Recovery Picks Up Pace

The Moderna boss believes enough vaccines could be available by the middle of next year to immunize the entire world—a challenge amid supply shortages and inequity in poorer nations.

Moderna CEO Says Pandemic Could Be Over Next Year As Vaccine Production Ramps Up

Moderna Inc's chief executive has predicted an end to the Covid pandemic within a year as the production of vaccines ramps up. Speaking to Swiss newspaper Neue Zuercher Zeitung Stéphane Bancel said: "As of today, in a year, I assume," when asked how long it would take for things to get back to normal.

Moderna boss predicts pandemic will end within a year

Pfizer

It's likely that millions of COVID-19 booster shots will be administered in the U.S. in the coming months, but that doesn't mean companies like Moderna Inc. and Pfizer Inc. will report an unexpected revenue windfall this year.

Whether the FDA approves a COVID-19 booster shot or not, Pfizer and Moderna have already made their money

Avantor Inc.

KLA-Tencor

ON Semiconductor

Quanta Services

We have narrowed down our search to five large-cap stocks that have gained nearly 5% or more than 5% month to date. These are: AVTR, PWR, ON, KLAC, and MRNA.

Top 5 High-Flying Stocks That Have Survived September Mayhem

There are a couple of big reasons why Moderna stock isn't as good of a pick as Pfizer right now.

Moderna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't

Johnson & Johnson

Housing Starts came in at 1.62 million, higher than the 1.55 million estimate, which happened to be the headline number for July.

Housing Data Better than Expected on Growth in Northeast

Fed's FOMC Meeting in Focus

MANHASSET, N.Y.--(BUSINESS WIRE)--In a new clinical trial looking at the efficacy of a third Moderna vaccine dose for coronavirus disease 2019 (COVID-19) in people living with an organ (liver or kidney) transplant, The Feinstein Institutes for Medical Research – the science arm of Northwell Health – administered the extra vaccine to the first set of patients in the United States on September 20. The multi-centered, nationwide clinical trial is sponsored by the vaccine-maker Moderna. People who

Moderna COVID-19 Vaccine Clinical Trial for People With Organ Transplant Starts at Feinstein Institutes

Booster shots could be coming, which would naturally be great for MRNA and its peers. Moderna will have an outstanding 2021, a strong 2022, but beyond that, the future is uncertain.

Is Moderna Stock A Buy Before Booster Program Rolls Out?

FIGS

If COVID-19 shocks the market again, our trio of Fools suggest that you might want to own shares of Moderna, Regeneron, and Figs.

3 COVID Stocks to Buy in a Bear Market

Bausch Health Companies Inc

Biogen

BioNTech SE

CRISPR Therapeutics

Teva Pharmaceutical

Viatris

SPDR S&P Pharmaceuticals ETF

With drug pricing reform on the horizon, investors may want to analyze their allocation.

Is Now the Time to Ditch Pharma Stocks?

Moderna has blasted through analysts' earnings this year and might keep doing that. FCF could end up much more than analysts foresee next year, pushing MRNA stock 44% higher to $618 per share.

Moderna Has Ripped Through Analyst Estimates This Year, and Might Not Stop

Do These Words From Moderna's President Mean Trouble for Vaccine Makers?

The company needs to do three things for its stock to soar another 100%.

How Moderna Stock Can Double From Here

Its high valuation is only part of the reason investors should consider selling their shares today.

Here's Why Moderna's Stock Could Crash Before the End of 2021

Moderna's Bigger Catalyst: Full FDA Approval or Booster Authorization?

Here's How to Avoid Missing the Next Moderna

All three coronavirus vaccines offer strong protection against hospitalization, the CDC said Friday — but one vaccine appeared to outpace the others.

Moderna Covid Vaccine More Effective Than Others In Preventing Hospitalization, CDC Finds

Moderna's vaccine is slightly more effective than Pfizer's or J&'s in preventing hospitalization, though the gap widens substantially after four months.

Moderna Vaccine More Effective Than Pfizer, J&J, Especially After 4 Months: CDC

Moderna's shot lowered the risk of hospitalization by 93%. Pfizer's vaccine lowered that risk by 88%.

Moderna's vaccine offers better protection against COVID-19 hospitalization than Pfizer or J&J, new CDC study finds

Debate over the need for COVID-19 booster shots is clouding the outlook for Moderna Inc's high-flying shares after the U.S. biotechnology company's stock price soared as much as 360% this year, making it the best performer in the S&P 500.

Analysis-Torrid Moderna stock rally cools over booster shot doubts

Novavax

Ocugen, Inc.

Investors are nervous about a Food and Drug Administration advisory panel meeting and optimistic about a World Health Organization decision.

Why COVID Vaccine Stocks BioNTech, Moderna, and Novavax Are Sliding While Ocugen Is Rising

A new study shows a striking difference between the Moderna and Pfizer vaccines.

News for Moderna Stock (MRNA)